Brokerages Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $49.22

Shares of Biomea Fusion, Inc. (NASDAQ:BMEAGet Free Report) have been given a consensus rating of “Moderate Buy” by the ten research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $49.22.

Several equities research analysts recently issued reports on BMEA shares. Citigroup reiterated a “buy” rating and issued a $90.00 price objective on shares of Biomea Fusion in a report on Friday, December 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Biomea Fusion in a report on Wednesday, March 6th. Finally, Truist Financial began coverage on Biomea Fusion in a report on Tuesday, February 6th. They set a “buy” rating and a $55.00 price objective on the stock.

Check Out Our Latest Report on BMEA

Institutional Investors Weigh In On Biomea Fusion

Institutional investors and hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. bought a new position in Biomea Fusion during the second quarter worth about $36,000. Signaturefd LLC bought a new position in Biomea Fusion during the fourth quarter worth about $36,000. UBS Group AG increased its holdings in shares of Biomea Fusion by 3,980.0% during the third quarter. UBS Group AG now owns 4,080 shares of the company’s stock worth $40,000 after buying an additional 3,980 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Biomea Fusion by 316.3% in the third quarter. Tower Research Capital LLC TRC now owns 3,251 shares of the company’s stock valued at $45,000 after purchasing an additional 2,470 shares in the last quarter. Finally, Grove Bank & Trust acquired a new stake in shares of Biomea Fusion in the fourth quarter valued at approximately $56,000. Institutional investors and hedge funds own 93.68% of the company’s stock.

Biomea Fusion Trading Down 2.8 %

Shares of BMEA opened at $15.32 on Friday. The stock’s 50 day moving average is $16.75 and its two-hundred day moving average is $14.33. The firm has a market cap of $547.08 million, a P/E ratio of -4.60 and a beta of -0.48. Biomea Fusion has a 12 month low of $8.13 and a 12 month high of $43.69.

Biomea Fusion Company Profile

(Get Free Report

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.

Featured Stories

Analyst Recommendations for Biomea Fusion (NASDAQ:BMEA)

Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.